A retrospective analysis of data from the National Cancer Data Base has found that patients who had cancer surgery at 56 days after the end of combined chemoradiotherapy presented with the best overall survival and successful removal of their residual tumors.
A retrospective analysis of data from the National Cancer Data Base (NCDB) has found that patients who had cancer surgery at precisely 8 weeks after the end of combined chemoradiotherapy presented with the best overall survival and successful removal of their residual tumors.
Colon and rectal cancers are the third most common cancers in the United States, according to the CDC, with about 135,000 new cases and 51,000 deaths per year.
Published in the Journal of the American College of Surgeons, the study included data from 11,760 patients with stage II and III rectal adenocarcinoma who went through chemoradiotherapy and surgical resection from 2006 to 2012. The primary outcomes that were evaluated were margin positivity, and tumor downstaging. Secondary outcomes evaluated were readmission and death rates within 30 days of hospital discharge and overall survival.
The study analysis divided patients into 2 groups: short-interval, those who underwent operations within 55 days of chemoradiotherapy; and long-interval, those who had an operation 56 days or more after radiotherapy. The long-interval group was slightly older (age 59 vs 58 years), more likely to be black (9.5% vs 8%), treated at an academic hospital, and less likely to have private insurance (50.2% vs 55.4%), and stage III disease (51.4% vs 54.2%).
The investigators found that the median time between chemoradiotherapy and surgery was 53 days, with a range of 43 to 63 days. After adjusting for patient demographic, clinical, tumor, and treatment characteristics, the period of 56 days was found to have the most impact on resection margin positivity and pathologic downstaging. Additionally, extending the delay beyond 56 days between radiation and surgery was associated with a higher likelihood of positive resection margins and compromised long-term survival, suggesting that longer waiting times may risk tumor regrowth.
“Due to its size, we thought NCDB was a perfect resource to answer the question about the timing of surgery after chemoradiotherapy for rectal cancer. The data set represented all types of hospitals,” said Christopher R. Mantyh, MD, FACS, senior author on the study, in a press release. According to Mantyh, the size of the study distinguishes the results from all previous studies that tried to answer the same question. The earlier studies, he said, had smaller patient cohorts and were from single institutions unlike the current study.
“In the global picture, there’s a lot of discussion about if waiting longer for surgery is better, and if you don’t wait as long there’s less chance of tumor spreading, but none of it is backed up on good modeling data like we have in this study,” Mantyh said. “This kind of analysis is what we need in medicine and surgery. We need to have good population based data.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More